DTG Won’t Be Forced On Citizens- Ministry

PEOPLE Living With HIV (PLHIV) and on Antiretroviral Therapy (ART) still have the option to continue taking other ART options apart from Dolutogravir (DTG) based regimens  since the process is not compulsory, a ministry of health and child care (MoHCC) official has said. By Michael Gwarisa in Gweru Zimbabwe commenced its transition process from Tenovir/Lamuvidene/Efavirens to Dolutegravir (DTG) in May 2019, and the transition procedure will be completed by February 2020. Briefing a women living with HIV, Sexual Reproductive Health and Rights (SRHR) workshop organised by PAPWC/ZIM,  ZWLHNF and UNAIDS,…

Share
Read More

#BREAKING: Zim To Switch To New ARV Drug With Less Side Effects

ZIMBABWE is ready to transition to Teno-Lamuvudine Dolutegrevir (TLD), an Anti-retro Viral (ARV) drug with less side effects, moving away from the Teno-Lamivudine-Efavirenz (TLE) a three in one drug that is taken once a day, a top health official has said By Michael Gwarisa The development comes barely a year after government through the Ministry of Health and Child Care (MoHCC) deferred rolling out of the Dolutegrevir drug following indications that it posed a great risk to women of child bearing age and adolescent girls which might lead to women…

Share
Read More